States Continue to Weigh Pros and Cons of Medicaid Expansion
States continue to weigh the pros and cons of Medicaid expansion in an effort to project whether the fiscal model is sustainable in the long term. Given the impact of such a huge decision, the 2014 deadline doesn’t seem that far away. Here are some of the latest news items around this debate.
FDASIA Places Emphasis on Patient-Focused Drug Development
On July 9, President Obama signed into law the US Food and Drug Administration Safety and Innovation Act (FDASIA). The bipartisan legislation is the culmination of more than a year of negotiations and aims to spur the development of lifesaving treatments and therapies for the approximately 30 million Americans who suffer from rare diseases.
The act also gives the FDA the authority to collect user fees from industry to fund reviews of innovator drugs, medical devices, generic drugs, and biosimilar biologics.
Overcoming High Costs to Provide Affordable Access to Cancer Care
As what happens many times when cancer drugs gain FDA approval, the statistically significant improvements in regards to prolonging patients’ lives is often offset by high drug costs, which makes it difficult for drug companies and payers to provide patients access to lifesaving treatments. But what can be done to improve access to affordable care?
Will The Affordable Care Act Ever Achieve Its Lofty Goal?
On June 28, 2012, the United States Supreme Court upheld the 2010 Patient Protection and Affordable Care Act (PPACA), setting into motion changes that will transform the way in which healthcare services are reimbursed and delivered. The result of this decision has sparked widespread debate on whether the PPACA will accomplish what it was intended to.